Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Winstanley plans lab space project for New Haven

A prominent developer is proposing to build 500,000 square feet of laboratory and life-sciences incubation space in downtown New Haven. Winstanley Enterprises LLC plans a major...

| By Kelley Gipson

New Haven’s Wellinks to be acquired by Convexity

Wellinks, a six-year-old New Haven startup founded by Yale students who invented an internet-connected brace-monitoring strap for scoliosis patients, has been acquired by Fairfield respiratory...

| By Kelley Gipson

Alexion plans Phase 3 Study Of ULTOMIRIS® re ALS

Alexion Pharmaceuticals is planning to initiate a pivotal Phase 3 study of ULTOMIRIS® (ravulizumab) in amyotrophic lateral sclerosis (ALS). The 50-week global study, called CHAMPION-ALS,...

| By Kelley Gipson

Rothberg’s Hyperfine scores with portable MRI

Hyperfine Research is pioneering a portable, point-of-care MRI it plans to market later this year for around $50,000, a fraction of the price of conventional...

| By Kelley Gipson

UConn: Repeats influence genome biology

About 50% of human DNA today is made of duplicated sequences that are the remnants of transposition events that took place in our evolutionary history....

| By Kelley Gipson

Bayer and Azitra collaborate on skin bacteria

Bayer and Azitra have announced a joint development agreement to collaborate in the identification and characterization of skin microbiome bacteria. The partnership will leverage Azitra’s...

| By Kelley Gipson

SpringWorks collaborates with Allogene re myeloma

SpringWorks Therapeutics has entered into a clinical trial collaboration agreement with Allogene Therapeutics.. This agreement will evaluate ALLO-715, Allogene’s investigational anti-B-cell maturation antigen (BCMA) AlloCAR...

| By Kelley Gipson

CBX-12 is Cybrexa’s new lead development program

Cybrexa Therapeutics has announced CBX-12 (alphalexTM-exatecan) as its new lead development program. CBX-12 is an alphalexTM conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12...

| By Kelley Gipson

IsoPlexis pulls in additional $20M funding

IsoPlexis has raised an additional $20 million in its Series C financing, bringing the entire Series C round to $45 million. The funding will continue to...